UnitedHealth Group Stock Is Up 39.4% in the Last 6 Months. How High Can It Go?
Key Points
UnitedHealth Group surged from April 2026 to July 2026, on strong earnings and improved sentiment about the health insurance company's turnaround efforts.
Even as strategies like increased AI investment may be starting to pay off, concerns about soaring health claims have likely contributed to the stock's pullback since the summer.
Until results say otherwise, assume the bull case remains in motion, and consider making UnitedHealth Group a long-term buy.
Over the past six months, UnitedHealth Group (NYSE: UNH) shares have been crushing it, surging by nearly 40% since March 2026. UnitedHealth, once a highflier among healthcare stocks, has benefited from a major shift in investor sentiment.
However, with the health insurance company's shares reversing course since July, the question is whether UnitedHealth Group will resume its upward trajectory or if this recent, disheartening price trend will persist, placing further pressure on the stock.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Image source: Getty Images.
Strong earnings and turnaround hopes sent UnitedHealth Group surging during mid-2026
Starting with its well-received Q1 earnings release, UnitedHealth Group kicked off an extended rally. Confidence in UnitedHealth Group's turnaround remained a top focus and was key to the stock's surge from $275 to as much as $461.62 between April and July 2026.
Analysts across Wall Street, including those at Goldman Sachs, BofA, and Morgan Stanley, have upgraded the stock, citing improving utilization trends, plus management's commentary that the company's $3 billion investment in artificial intelligence is already paying off two-to-one.
Since hitting new 52-week highs during the summer, UnitedHealth Group shares have once again experienced waning enthusiasm.
The long-term silver lining
Now trading for just under $400 per share, has a "buy the dip" moment emerged? Maybe, maybe not. Worries about fundamentals, not just profit-taking, may be driving the stock's weak post-earnings price action.
Even as favorable utilization trends and cost-cutting measures continue to boost the bottom line, on the Q2 2026 post-earnings conference call, management discussed how issues like independent dispute resolutions, as well as increased coverage of GLP-1 and anti-inflammatory drugs, remain key concerns when it comes to rising cost trends.
Trading for 18 times estimated 2027 earnings, UnitedHealth appears reasonably priced compared to its historical valuation. Still, if management's AI-driven turnaround pans out and drives expected earnings growth in the mid-to-high teens over the next three years, recent volatility could seem like a hiccup in hindsight. As the company continues to release strong quarterly results, the stock appears to remain a solid long-term buy, even if recent volatility persists in the near-term.
Thomas Niel has positions in UnitedHealth Group. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy.